Ruchi Saxena - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Ruchi Saxena

Showing results (41-50 of 43) with videos related to

Pageof 5

Sort By:

You have reached the last page of results.This site can display upto 43 results.

Oncogenesis|February 24, 2019

Study of Cathepsin B inhibition in VEGFR TKI treated human renal cell carcinoma xenograftsChun-Hau Chen, Swati Bhasin, Prateek Khanna, et al.

Science Translational Medicine|January 21, 2021

ACE2 abrogates tumor resistance to VEGFR inhibitors suggesting angiotensin-(1-7) as a therapy for clear cell renal cell carcinomaPrateek Khanna, Hong Jie Soh, Chun-Hau Chen, et al.

Nature Communications|January 3, 2025

Complement factor H targeting antibody GT103 in refractory non-small cell lung cancer: a phase 1b dose escalation trialJeffrey M Clarke, George R Simon, Hirva Mamdani, et al.

Pageof 5

Search research articles

Showing results (41-50 of 43) with videos related to

Sort By:

Pageof 5

You have reached the last page of results.This site can display upto 43 results.

Oncogenesis|February 24, 2019

Study of Cathepsin B inhibition in VEGFR TKI treated human renal cell carcinoma xenograftsChun-Hau Chen, Swati Bhasin, Prateek Khanna, et al.

Science Translational Medicine|January 21, 2021

ACE2 abrogates tumor resistance to VEGFR inhibitors suggesting angiotensin-(1-7) as a therapy for clear cell renal cell carcinomaPrateek Khanna, Hong Jie Soh, Chun-Hau Chen, et al.

Nature Communications|January 3, 2025

Complement factor H targeting antibody GT103 in refractory non-small cell lung cancer: a phase 1b dose escalation trialJeffrey M Clarke, George R Simon, Hirva Mamdani, et al.

Pageof 5